SCHEMBL5570265

SCHEMBL5570265

CCc1cc(CCCc2ccc(CO)c(CO)c2)ccc1OCC(O)C(C(F)(F)F)C(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.35
PPARA Q07869 2/20 0.35
PPARD Q03181 1/20 0.35
VDR P11473 4/20 0.34
PPARG P37231 1/20 0.31
S1PR1 P21453 2/20 0.31
HTT P42858 3/20 0.31
MAPT P10636 2/20 0.31
MAPK1 P28482 2/20 0.31
S1PR3 Q99500 1/20 0.31
S1PR5 Q9H228 1/20 0.31
APAF1 O14727 1/20 0.31
THRB P10828 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
AKT1 P31749 1/20 0.31
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
NPC1 O15118 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
RAD52 P43351 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5568696 0.89 FFAR4 (0.37) FFAR4VDR
SCHEMBL5569478 0.89 FFAR4 (0.39) FFAR4PPARAPPARDVDRPPARG
SCHEMBL5569570 0.87 VDR (0.36) FFAR4PPARAPPARDVDRPPARG
SCHEMBL5564865 0.87 VDR (0.38) FFAR4PPARAPPARDVDRPPARG
SCHEMBL5565702 0.86 ALDH1A1 (0.34) VDRHTTMAPTMAPK1APAF1
SCHEMBL5569395 0.83 S1PR1 (0.32) FFAR4S1PR1
SCHEMBL5564788 0.83 VDR (0.45) VDR
SCHEMBL5564986 0.78 VDR (0.33) VDR
SCHEMBL5570821 0.77 VDR (0.41) FFAR4VDR
SCHEMBL5565409 0.77 VDR (0.38) FFAR4VDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312249-B2 Vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-12-25 US claimed
US-20050182144-A1 Novel vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-18 US claimed
US-7312249-B2 Vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-12-25 US disclosed
US-20050182144-A1 Novel vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182144-A1 Novel vitamin D analogues CYP24A1, CYP2R1, VDR FFAR4 347/4885PPARA 134/4885PPARD 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.